ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT03638167
Previous Study | Return to List | Next Study

EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03638167
Recruitment Status : Not yet recruiting
First Posted : August 20, 2018
Last Update Posted : October 3, 2018
Sponsor:
Information provided by (Responsible Party):
Julie Park, Seattle Children's Hospital

Brief Summary:
This is a Phase 1 study of central nervous system (CNS) locoregional adoptive therapy with autologous CD4+ and CD8+ T cells that are lentivirally transduced to express an EGFR806 specific chimeric antigen receptor (CAR) and EGFRt. CAR T cells are delivered via an indwelling catheter into the tumor resection cavity or the ventricular system in children and young adults with recurrent or refractory EGFR-positive CNS tumors. The primary objectives of this protocol are to evaluate the feasibility, safety, and tolerability of CNS-delivered fractionated CAR T cell infusions employing intra-patient dose escalation. Subjects with supratentorial tumors will receive sequential EGFR806-specific CAR T cells delivered into the tumor resection cavity, subjects with infratentorial tumors will receive sequential CAR T cells delivered into the fourth ventricle, and subjects with leptomeningeal disease will receive sequential CAR T cells delivered into the lateral ventricle. The secondary objectives are to assess CAR T cell distribution within the cerebrospinal fluid (CSF), the extent to which CAR T cells egress into the peripheral circulation, and EGFR expression at recurrence of initially EGFR-positive tumors. Additionally, tumor response will be evaluated by magnetic resonance imaging (MRI) and CSF cytology. The exploratory objectives are to analyze CSF specimens for biomarkers of anti-tumor CAR T cell presence and functional activity.

Condition or disease Intervention/treatment Phase
Central Nervous System Tumor, Pediatric Glioma Ependymoma Medulloblastoma Germ Cell Tumor Atypical Teratoid/Rhabdoid Tumor Primitive Neuroectodermal Tumor Choroid Plexus Carcinoma Pineoblastoma Biological: EGFR806-specific chimeric antigen receptor (CAR) T cell Phase 1

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 36 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Study of EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric Central Nervous System Tumors
Estimated Study Start Date : October 2018
Estimated Primary Completion Date : November 2021
Estimated Study Completion Date : November 2036


Arm Intervention/treatment
Experimental: ARM A (Tumor Cavity Infusion)
Patients with supratentorial tumors for which CAR T cells will be delivered into the tumor resection cavity
Biological: EGFR806-specific chimeric antigen receptor (CAR) T cell
Autologous CD4+ and CD8+ T cells lentivirally transduced to express a EGFR806 specific chimeric antigen receptor (CAR) and EGFRt given via indwelling central nervous system (CNS) catheter

Experimental: ARM B (Ventricular System Infusion)
Patients with either infratentorial tumors or leptomeningeal tumors for which the CAR T cells will be delivered into the fourth ventricle or lateral ventricle, respectively
Biological: EGFR806-specific chimeric antigen receptor (CAR) T cell
Autologous CD4+ and CD8+ T cells lentivirally transduced to express a EGFR806 specific chimeric antigen receptor (CAR) and EGFRt given via indwelling central nervous system (CNS) catheter




Primary Outcome Measures :
  1. Safety: any adverse events associated with one or multiple EGFR806-specific CAR T cell product infusions will be assessed by CTCAE v5.0. [ Time Frame: up to 6 months ]
    The type, frequency, severity, and duration of adverse events as a result of EGFR806-specific CAR T cell infusion will be summarized

  2. Feasibility: The number of successfully manufactured and infused EGFR806-specific CAR T cell product [ Time Frame: 28 days ]
    The proportion of products successfully manufactured and infused will be measured


Secondary Outcome Measures :
  1. CAR T cell distribution: The number of subjects with CAR T cell persistence in the cerebrospinal fluid (CSF) and peripheral blood as measured by flow cytometry [ Time Frame: up to 6 months ]
    The trafficking of the EGFR806-specific CAR T cell product through the CSF by measuring remaining CAR T cells from a prior infusion at the time of each infusion and the trafficking of EGFR806-specific CAR T cells from the CSF into the peripheral blood will be evaluated.

  2. Expression of target epitope: assessment of whether EGFR expression changes in relapsed CNS tumors that were EGFR positive prior to treatment with CAR T cells via immunohistochemistry on resected tissue samples. [ Time Frame: 28 days ]
    The changes in EGFR expression at diagnosis and recurrence of central nervous system (CNS) tumors, if samples from multiple time points is available, will be investigated by evaluating pathology specimens from previous surgeries

  3. Disease response: Assessment of disease response of EGFR-expressing refractory or recurrent central nervous system (CNS) tumors to EGFR806 specific CAR T cell therapy delivered directly into the CNS by cytology and radiology criteria. [ Time Frame: up to 6 months ]
    The response of recurrent or refractory central EGFR-expressing CNS tumors to EGFR806-specific CAR T cell therapy delivered directly into the CNS will be determined by evaluating CSF for tumor cells and by CNS imaging with MRIs.


Other Outcome Measures:
  1. Quantitative biomarker assessment of anti tumor CAR T cell functional activity [ Time Frame: up to 6 months ]
    The presence of biomarkers of anti-tumor CAR T cell functional activity, such as cytokines, will be quantified via protein expression analysis in CSF. These findings will be correlated with response by disease evaluations via CSF cytology and MRI imaging of the CNS.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   1 Year to 26 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • First 3 enrolled subjects: age ≥ 15 and ≤ 26 years Subsequent subjects: age ≥ 1 and ≤ 26 years
  • Histologically diagnosed EGFR positive Central Nervous System (CNS) tumor
  • Evidence of refractory or recurrent CNS disease that has failed first-line therapy
  • Willing and able to provide tumor specimens
  • Able to tolerate apheresis
  • Functional CNS reservoir catheter, such as an Ommaya or Rickham catheter
  • Life expectancy ≥ 8 weeks
  • Lansky or Karnofsky score ≥ 50
  • Recovered from acute toxic effects of all prior chemotherapy, immunotherapy, and radiotherapy
  • ≥ 7 days post last chemotherapy administration
  • 3 half lives or 30 days, whichever is shorter post last dose of anti-tumor antibody therapy
  • No prior virotherapy. Prior genetically modified cell therapy is allowed if not detectable at enrollment.
  • Stable or decreasing dosing of steroid treatment for symptomatic relief from CNS disease, with maximum dexamethasone dose of 2.5 mg/m2/day
  • Adequate organ function
  • Adequate laboratory values
  • Patients of childbearing/fathering potential must agree to use highly effective contraception
  • Signed a written consent

Exclusion Criteria:

  • Diagnosis of classic diffuse intrinsic pontine glioma (DIPG)
  • Presence of ≥ Grade 3 cardiac dysfunction or symptomatic arrhythmia requiring intervention
  • Presence of primary immunodeficiency/bone marrow failure syndrome
  • Presence of clinical and/or radiographic evidence of impending herniation
  • Presence of active malignancy other than the primary CNS tumor under study
  • Presence of active severe infection
  • Receiving any anti-cancer agents or chemotherapy
  • Pregnant or breastfeeding
  • Unwilling to provide consent/assent for participation in the 15 year follow up period
  • Presence of any condition that, in the opinion of the investigator, would prohibit the patient from undergoing treatment under this protocol

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03638167


Contacts
Contact: Juliane Gust, MD, PhD 206-987-2106 immunotherapy@seattlechildrens.org
Contact: Nicholas Vitanza, MD 206-987-2106 immunotherapy@seattlechildrens.org

Locations
United States, Washington
Seattle Children's Hospital Not yet recruiting
Seattle, Washington, United States, 98105
Contact: Juliane Gust, MD, PhD         
Contact: Nicholas Vitanza, MD         
Principal Investigator: Juliane Gust, MD, PhD         
Sponsors and Collaborators
Seattle Children's Hospital
Investigators
Study Chair: Juliane Gust, MD, PhD Seattle Children's Hospital

Responsible Party: Julie Park, Medical Director, Immunotherapy Coordinating Center, Seattle Children's Hospital
ClinicalTrials.gov Identifier: NCT03638167     History of Changes
Other Study ID Numbers: BrainChild-02
First Posted: August 20, 2018    Key Record Dates
Last Update Posted: October 3, 2018
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Julie Park, Seattle Children's Hospital:
CNS, CAR T cell, EGFR-positive
pediatric, young adults, brain tumor

Additional relevant MeSH terms:
Neoplasms
Neoplasms, Germ Cell and Embryonal
Ependymoma
Nervous System Neoplasms
Central Nervous System Neoplasms
Medulloblastoma
Neuroectodermal Tumors
Neuroectodermal Tumors, Primitive
Rhabdoid Tumor
Pinealoma
Neoplasms by Histologic Type
Glioma
Neoplasms, Neuroepithelial
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms by Site
Nervous System Diseases
Neoplasms, Complex and Mixed
Brain Neoplasms
Brain Diseases
Central Nervous System Diseases